{"id":"NCT01927861","sponsor":"Novo Nordisk A/S","briefTitle":"Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome","officialTitle":"A 52-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Short Stature With Noonan Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08-19","primaryCompletion":"2018-07-12","completion":"2018-07-12","firstPosted":"2013-08-23","resultsPosted":"2019-10-14","lastUpdate":"2020-08-10"},"enrollment":51,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Genetic Disorder","Noonan Syndrome"],"interventions":[{"type":"DRUG","name":"somatropin","otherNames":[]}],"arms":[{"label":"0.033 mg/kg/day","type":"EXPERIMENTAL"},{"label":"0.066 mg/kg/day","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in Asia. The aim of the trial is to investigate the long-term efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan syndrome.","primaryOutcome":{"measure":"Change in Height SDS (Japanese National Reference Data)","timeFrame":"Baseline, week 104","effectByArm":[{"arm":"NN-220 0.033 mg/kg/Day","deltaMin":0.84,"sd":0.09},{"arm":"NN-220 0.066 mg/kg/Day","deltaMin":1.47,"sd":0.09}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":27,"countries":["Japan"]},"refs":{"pmids":["32269181","29109363"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":25},"commonTop":["Nasopharyngitis","Influenza","Gastroenteritis","Pyrexia","Upper respiratory tract infection"]}}